United Therapeutics (UTHR) to Post Quarterly Earnings on Wednesday

Posted by Geri Gentry on Jul 22nd, 2026

United Therapeutics (NASDAQ:UTHR – Get Free Report) is projected to announce its Q2 2026 results before the market opens on Wednesday, July 29th. Analysts expect United Therapeutics to announce earnings of $7.06 per share and revenue of $805.0090 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Wednesday, July 29, 2026 at 9:00 AM ET.

United Therapeutics (NASDAQ:UTHR – Get Free Report) last announced its quarterly earnings data on Wednesday, May 6th. The biotechnology company reported $5.82 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $7.00 by ($1.18). The company had revenue of $781.50 million for the quarter, compared to the consensus estimate of $797.40 million. United Therapeutics had a net margin of 40.62% and a return on equity of 19.24%. The firm’s quarterly revenue was down 1.6% compared to the same quarter last year. During the same period last year, the business posted $6.63 earnings per share. On average, analysts expect United Therapeutics to post $27 EPS for the current fiscal year and $32 EPS for the next fiscal year.

United Therapeutics Trading Up 1.2%

UTHR opened at $535.83 on Wednesday. The company has a market cap of $22.75 billion, a P/E ratio of 19.78, a P/E/G ratio of 1.77 and a beta of 0.58. The business’s 50-day moving average price is $550.65 and its 200-day moving average price is $530.90. United Therapeutics has a 12 month low of $272.12 and a 12 month high of $609.35.

Insider Transactions at United Therapeutics

In other news, CFO James Edgemond sold 10,000 shares of the firm’s stock in a transaction dated Monday, April 27th. The shares were sold at an average price of $568.83, for a total value of $5,688,300.00. Following the completion of the sale, the chief financial officer directly owned 18,876 shares of the company’s stock, valued at approximately $10,737,235.08. This trade represents a 34.63% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Over the last quarter, insiders have sold 535,379 shares of company stock worth $299,468,343. 8.60% of the stock is currently owned by insiders.

Hedge Funds Weigh In On United Therapeutics

A number of institutional investors have recently bought and sold shares of UTHR. American Trust bought a new stake in United Therapeutics during the 4th quarter valued at approximately $210,000. Abel Hall LLC bought a new position in shares of United Therapeutics in the 4th quarter worth approximately $201,000. Smartleaf Asset Management LLC raised its position in shares of United Therapeutics by 30.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 330 shares of the biotechnology company’s stock worth $164,000 after acquiring an additional 77 shares in the last quarter. Quattro Advisors LLC purchased a new position in shares of United Therapeutics in the 4th quarter valued at approximately $131,000. Finally, Northwestern Mutual Wealth Management Co. lifted its stake in shares of United Therapeutics by 18.8% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 443 shares of the biotechnology company’s stock valued at $127,000 after purchasing an additional 70 shares during the period. 94.08% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities research analysts recently weighed in on the company. Morgan Stanley set a $516.00 target price on United Therapeutics in a report on Thursday, May 7th. Wells Fargo & Company upgraded United Therapeutics from an “equal weight” rating to an “overweight” rating and boosted their price objective for the company from $575.00 to $735.00 in a research report on Thursday, May 7th. TD Cowen reissued a “buy” rating on shares of United Therapeutics in a research note on Thursday, May 21st. Royal Bank Of Canada raised their target price on shares of United Therapeutics from $701.00 to $704.00 and gave the stock an “outperform” rating in a report on Tuesday, July 7th. Finally, Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a research report on Thursday, June 11th. Ten equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat.com, United Therapeutics currently has an average rating of “Moderate Buy” and an average target price of $644.82.

Get Our Latest Stock Analysis on United Therapeutics

United Therapeutics Company Profile

(Get Free Report)

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.

Earnings History for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.